• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Safilo Group reports strong growth in first half

Article

Padova, Italy-Safilo Group reported that its strong growth trend continued during the first half of 2004, with a consolidated turnover that reached $615.6 million.

Padova, Italy-Safilo Group reported that its strong growth trend continued during the first half of 2004, with a consolidated turnover that reached $615.6 million.

The company said the figure represents an increase of 12.1% and 7.6% at current exchange rates compared with the first 6 months of 2003. The second quarter of 2004 was particularly strong, with an increase of 8.9% over the same period last year. Earnings before interest, depreciation, and amortization were listed as $97.9 million.

Safilo noted growth in the Far East and the United States.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
© 2024 MJH Life Sciences

All rights reserved.